Form 4: ANAB Director Magda Marquet Granted Equity Awards

AnaptysBio Director Magda Marquet received 5,500 stock options and 4,000 restricted stock units as part of her compensation.

Summary

• Director Magda Marquet was granted 5,500 stock options with an exercise price of $43.91 on January 6, 2026.
• These stock options will vest at a rate of 1/12 of the total shares monthly, commencing on February 6, 2026, until fully vested, contingent on her continued service.
• The stock options have an expiration date of January 5, 2036.
• Marquet also received 4,000 Restricted Stock Units (RSUs) on January 6, 2026.
• These RSUs will vest 100% on the date of AnaptysBio's 2027 annual meeting of shareholders, subject to her continued provision of service.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The filing reports routine equity compensation for a director, which is generally a neutral to slightly positive event as it aligns management interests with shareholders. No significant positive or negative operational news is present.

Positives

• Director Magda Marquet's increased equity stake aligns her interests with those of the shareholders, potentially fostering long-term value creation.
• The grants are part of a pre-planned Rule 10b5-1(c) arrangement, indicating a structured and transparent approach to executive compensation.

Risks

• The ultimate value realized from the stock options and RSUs is contingent on the future market performance of ANAPTYSBIO, INC.'s common stock.
• Vesting of both the stock options and RSUs is subject to Magda Marquet's continued provision of service to the Issuer on each respective vesting date.

Future Outlook

The vesting schedules for the stock options and Restricted Stock Units extend into 2026 and 2027, indicating a long-term commitment from the director and a forward-looking compensation structure tied to future company performance and shareholder value.

Industry Context

This filing reflects standard equity compensation practices for directors in the biotechnology industry, aiming to incentivize long-term commitment and align leadership interests with shareholder value creation. Such grants are a common component of executive and director compensation packages.

Stakeholder Impact

• Shareholders: The director's increased equity ownership further aligns her interests with those of shareholders, potentially fostering a focus on long-term value creation.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• Continued monthly vesting of stock options starting February 6, 2026.
• Vesting of Restricted Stock Units on the date of the 2027 annual meeting of shareholders.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a director, which is a standard practice to align management incentives with shareholder interests. It does not contain any new operational, financial, or strategic information that would warrant a change in investment recommendation. The grants are part of a pre-planned Rule 10b5-1 program, further indicating a non-eventful, scheduled transaction. Investors should continue to hold based on the company's fundamentals and broader market conditions, as this filing provides no new basis for a 'buy' or 'sell' decision.

Keywords

ANAPTYSBIO, ANAB, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Magda Marquet, Rule 10b5-1